Cargando…
Blinded continuous monitoring in clinical trials with recurrent event endpoints
In studies with recurrent event endpoints, misspecified assumptions of event rates or dispersion can lead to underpowered trials or overexposure of patients. Specification of overdispersion is often a particular problem as it is usually not reported in clinical trial publications. Changing event rat...
Autores principales: | Friede, Tim, Häring, Dieter A., Schmidli, Heinz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587844/ https://www.ncbi.nlm.nih.gov/pubmed/30345693 http://dx.doi.org/10.1002/pst.1907 |
Ejemplares similares
-
A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations
por: Huber, Cynthia, et al.
Publicado: (2019) -
Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data
por: Kunz, Cornelia Ursula, et al.
Publicado: (2014) -
On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies
por: Unkel, Steffen, et al.
Publicado: (2018) -
Reference‐based sensitivity analysis for time‐to‐event data
por: Atkinson, Andrew, et al.
Publicado: (2019) -
Imputation of missing covariate in randomized controlled trials with a continuous outcome: Scoping review and new results
por: Kayembe, Mutamba T., et al.
Publicado: (2020)